Pages that link to "Q27852141"
Jump to navigation
Jump to search
The following pages link to An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. (Q27852141):
Displaying 50 items.
- Mutational profiling of kinases in glioblastoma (Q21261249) (← links)
- Novel drugs that target the metabolic reprogramming in renal cell cancer (Q26740187) (← links)
- DNA repair mechanisms and their clinical impact in glioblastoma (Q26740256) (← links)
- Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives (Q26744441) (← links)
- Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy (Q26749870) (← links)
- The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets (Q26751224) (← links)
- Epigenetic regulators and their impact on therapy in acute myeloid leukemia (Q26765402) (← links)
- Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs (Q26766039) (← links)
- An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma (Q26784091) (← links)
- Dysregulated metabolism contributes to oncogenesis (Q26784630) (← links)
- In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies (Q26820289) (← links)
- New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma (Q26863394) (← links)
- Defining the metabolome: size, flux, and regulation (Q26865192) (← links)
- Connections between TET proteins and aberrant DNA modification in cancer (Q26865671) (← links)
- Concise review: Leukemia stem cells in personalized medicine (Q26995268) (← links)
- IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma (Q26995506) (← links)
- The next steps in next-gen sequencing of cancer genomes (Q26998894) (← links)
- Isocitrate dehydrogenase mutations: new opportunities for translational research (Q27001014) (← links)
- Molecular biology of gliomas: present and future challenges (Q27001295) (← links)
- Cholangiocarcinoma (Q27001694) (← links)
- Novel therapeutic targets of tumor metabolism (Q27005930) (← links)
- CIViC database (Q27612411) (← links)
- Next generation sequencing of acute myeloid leukemia: influencing prognosis (Q27690776) (← links)
- IDH mutations in tumorigenesis and their potential role as novel therapeutic targets (Q27692015) (← links)
- New IDH1 mutant inhibitors for treatment of acute myeloid leukemia (Q27702240) (← links)
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas (Q27853175) (← links)
- IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives (Q28066926) (← links)
- Undercover: gene control by metabolites and metabolic enzymes (Q28072281) (← links)
- Epigenetic Modulation as a Therapeutic Prospect for Treatment of Autoimmune Rheumatic Diseases (Q28079715) (← links)
- Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment (Q28081657) (← links)
- Metabolic consequences of oncogenic IDH mutations (Q28082949) (← links)
- Oncometabolites: tailoring our genes (Q28085392) (← links)
- The Role of Glucose Modulation and Dietary Supplementation in Patients With Central Nervous System Tumors (Q28087476) (← links)
- 2-Hydoxyglutarate: D/Riving Pathology in gLiomaS (Q28087807) (← links)
- IDH1 R132C (Q28371000) (← links)
- IDH1 R132H (Q28371383) (← links)
- Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification (Q28383205) (← links)
- Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms (Q29039802) (← links)
- Neuro-oncology: Five new things (Q30415098) (← links)
- Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. (Q30572367) (← links)
- Advances in the management of paediatric high-grade glioma (Q30870633) (← links)
- In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T. (Q31060593) (← links)
- Non-invasive metabolic imaging of brain tumours in the era of precision medicine (Q31115540) (← links)
- Detection of 2-hydroxyglutarate in brain tumors by triple-refocusing MR spectroscopy at 3T in vivo (Q31117278) (← links)
- Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data (Q31121880) (← links)
- Molecular pathology of bone tumours: diagnostic implications (Q33275105) (← links)
- Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. (Q33619309) (← links)
- Targeting tumor suppressor networks for cancer therapeutics (Q33657519) (← links)
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. (Q33698756) (← links)
- IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway (Q33709922) (← links)
